SCHEMBL4892901

SCHEMBL4892901

CC(C)(C)[Si](C)(C)Oc1ccc(-c2ccc(/C=N/O)cc2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PREP P48147 4/20 0.37
PKM P14618 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CA12 O43570 4/20 0.33
CA1 P00915 4/20 0.33
CA9 Q16790 4/20 0.33
APP P05067 2/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK1 P28482 1/20 0.33
GFER P55789 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892908 1.00 PREP (0.37) PREPPKMKDM4EALDH1A1L3MBTL1
SCHEMBL4892044 0.85 PREP (0.41) PREPKDM4EALDH1A1MEN1KMT2A
SCHEMBL4024645 0.81 KMT2A (0.49) PREPKDM4EALDH1A1MEN1KMT2A
SCHEMBL4024641 0.81 KMT2A (0.49) PREPKDM4EALDH1A1MEN1KMT2A
SCHEMBL4896622 0.75 ESR1 (0.46) PKMKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL4896627 0.75 ESR1 (0.46) PKMKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL8455901 0.70 BRD4 (0.37) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4896601 0.69 KMT2A (0.40) PREPKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL4896594 0.69 KMT2A (0.40) PREPKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL23491348 0.69 PREP (0.57) PREPKDM4EKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents WYETH (US) 2008-02-07 US disclosed
US-7279600-B2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents WYETH (US) 2007-10-09 US disclosed
EP-1808429-A2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents Wyeth a Corporation of the State of Delaware (US) 2007-07-18 EP disclosed
EP-1620392-B1 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS WYETH CORP (US) 2007-06-27 EP disclosed
US-20050020676-A1 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents WYETH 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents ESR1, ESR2, ESRRB PREP 2705/4885PKM 4115/4885KDM4E 212/4885
US-20050020676-A1 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents ESR1, ESR2, ESRRB PREP 2705/4885PKM 4115/4885KDM4E 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.